Matt D. Galsky

2.5k total citations
198 papers, 1.8k citations indexed

About

Matt D. Galsky is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Matt D. Galsky has authored 198 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 139 papers in Surgery, 114 papers in Oncology and 64 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Matt D. Galsky's work include Bladder and Urothelial Cancer Treatments (138 papers), Cancer Immunotherapy and Biomarkers (83 papers) and Multiple and Secondary Primary Cancers (44 papers). Matt D. Galsky is often cited by papers focused on Bladder and Urothelial Cancer Treatments (138 papers), Cancer Immunotherapy and Biomarkers (83 papers) and Multiple and Secondary Primary Cancers (44 papers). Matt D. Galsky collaborates with scholars based in United States, Italy and Germany. Matt D. Galsky's co-authors include Samuel J. Vidal, Carlos Cordon‐Cardo, Verónica Rodríguez-Bravo, Josep Domingo‐Domenech, Guru Sonpavde, Andrea Necchi, Thomas Powles, Shilpa Gupta, Asma Latif and Tomohiro Funakoshi and has published in prestigious journals such as Journal of Clinical Oncology, Oncogene and The Journal of Urology.

In The Last Decade

Matt D. Galsky

188 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matt D. Galsky United States	21	1.0k	982	445	407	196	198	1.8k
Elaina M. Gartner United States	18	683 0.7×	964 1.0×	430 1.0×	281 0.7×	302 1.5×	40	1.7k
Anders Ullén Sweden	18	646 0.6×	449 0.5×	398 0.9×	386 0.9×	84 0.4×	88	1.3k
Arash Rezazadeh Kalebasty United States	14	442 0.4×	630 0.6×	364 0.8×	531 1.3×	102 0.5×	69	1.2k
Mototsugu Muramaki Japan	22	429 0.4×	424 0.4×	625 1.4×	582 1.4×	105 0.5×	90	1.4k
Alessandra di Pietro Italy	21	639 0.6×	1.1k 1.1×	667 1.5×	687 1.7×	221 1.1×	95	1.9k
Álvaro S. Sarkis Brazil	14	483 0.5×	377 0.4×	559 1.3×	439 1.1×	85 0.4×	34	1.3k
Javier Puente Spain	18	320 0.3×	786 0.8×	424 1.0×	639 1.6×	101 0.5×	164	1.5k
Malcolm Crundwell United Kingdom	15	875 0.9×	328 0.3×	521 1.2×	514 1.3×	83 0.4×	28	1.6k
Thorsten Ecke Germany	22	681 0.7×	288 0.3×	414 0.9×	417 1.0×	54 0.3×	107	1.4k
Cynthia Kuk Canada	21	765 0.8×	306 0.3×	256 0.6×	389 1.0×	69 0.4×	42	1.5k

Countries citing papers authored by Matt D. Galsky

Since Specialization

Citations

This map shows the geographic impact of Matt D. Galsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matt D. Galsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matt D. Galsky more than expected).

Fields of papers citing papers by Matt D. Galsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matt D. Galsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matt D. Galsky. The network helps show where Matt D. Galsky may publish in the future.

Co-authorship network of co-authors of Matt D. Galsky

This figure shows the co-authorship network connecting the top 25 collaborators of Matt D. Galsky. A scholar is included among the top collaborators of Matt D. Galsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matt D. Galsky. Matt D. Galsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Galsky, Matt D., Enrique Grande, Andrea Necchi, et al.. (2024). Phase 3 study of disitamab vedotin with pembrolizumab vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001).. Journal of Clinical Oncology. 42(16_suppl). TPS4616–TPS4616.

Galsky, Matt D., Guru Sonpavde, Thomas Powles, et al.. (2024). Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial.. Journal of Clinical Oncology. 42(16_suppl). 4509–4509. 11 indexed citations

Laliotis, George, Shivaram Cumarasamy, Samuel Rivero-Hinojosa, et al.. (2024). Performance of a tumor-informed molecular residual disease (MRD) assay in resected bladder cancer with mixed or pure variant histology: Analysis of a real-world multicenter cohort.. Journal of Clinical Oncology. 42(4_suppl). 649–649. 1 indexed citations

Galsky, Matt D., Kyrollis Attalla, John P. Sfakianos, et al.. (2024). Tumor characteristics associated with detectable circulating tumor DNA preoperatively in patients with renal masses suspicious for RCC.. Journal of Clinical Oncology. 42(4_suppl). 461–461.

Gupta, Shilpa, Karla V. Ballman, Andrea B. Apolo, et al.. (2024). MAIN-CAV: Phase III randomized trial of maintenance cabozantinib (CABO) and avelumab (Av) vs Av after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).. Journal of Clinical Oncology. 42(4_suppl). TPS714–TPS714. 2 indexed citations

Halabi, Susan, Bin Luo, Todd P. Knutson, et al.. (2024). A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance).. Journal of Clinical Oncology. 42(16_suppl). 5007–5007.

Grande, Enrique, Aristotelis Bamias, Matt D. Galsky, et al.. (2023). Overall survival (OS) by response to first-line (1L) induction treatment with atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with metastatic urothelial carcinoma (mUC): Updated data from the IMvigor130 OS final analysis.. Journal of Clinical Oncology. 41(16_suppl). 4503–4503. 5 indexed citations

Gupta, Shilpa, Karla V. Ballman, Matt D. Galsky, et al.. (2023). MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).. Journal of Clinical Oncology. 41(16_suppl). TPS4609–TPS4609. 1 indexed citations

Heijden, Michiel S. van der, Guru Sonpavde, Thomas Powles, et al.. (2023). LBA7 Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: Results from the phase III CheckMate 901 trial. Annals of Oncology. 34. S1341–S1341. 9 indexed citations

10.

Galsky, Matt D., Jürgen E. Gschwend, Michael Schenker, et al.. (2023). Extended follow-up results from the CheckMate 274 trial.. Journal of Clinical Oncology. 41(6_suppl). LBA443–LBA443. 13 indexed citations

11.

Shore, Neal D., Thomas Powles, Jens Bedke, et al.. (2022). A phase 3 study of the subcutaneous programmed cell death protein 1 inhibitor sasanlimab as single agent for patients with bacillus Calmette-Guérin, unresponsiv,e high-risk, non-muscle invasive bladder cancer: CREST Study Cohort B.. Journal of Clinical Oncology. 40(16_suppl). TPS4614–TPS4614. 2 indexed citations

12.

Bajorin, Dean F., J. Alfred Witjes, Jürgen E. Gschwend, et al.. (2021). First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC).. Journal of Clinical Oncology. 39(6_suppl). 391–391. 30 indexed citations

13.

Wirtz, Heidi S., et al.. (2021). PCN118 Estimated Prevalence of Treated Locally Advanced or Metastatic Urothelial Carcinoma in Canada Using Simulation Modeling. Value in Health. 24. S41–S41. 1 indexed citations

14.

Doroshow, Deborah B., Andrew Schmidt, Ziad Bakouny, et al.. (2020). LBA74 Disparities in cancer during the COVID-19 pandemic: COVID-19 and cancer outcomes study (CCOS). Annals of Oncology. 31. S1204–S1204. 4 indexed citations

15.

Powles, Thomas, Michiel S. van der Heijden, D. Castellano Gauna, et al.. (2020). 697O A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE). Annals of Oncology. 31. S550–S551. 16 indexed citations

16.

Yap, Timothy A., J. Thaddeus Beck, Ross Stewart, et al.. (2018). JAVELIN PARP medley: A phase Ib/II study of avelumab (anti–PD-L1) plus talazoparib in locally advanced or metastatic solid tumors. Annals of Oncology. 29. viii441–viii441. 5 indexed citations

17.

Galsky, Matt D., Noah M. Hahn, Costantine Albany, et al.. (2016). Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer.. Journal of Clinical Oncology. 34(2_suppl). 357–357. 33 indexed citations

18.

Maughan, Benjamin L., Kenneth M. Boucher, Neeraj Agarwal, et al.. (2012). Correlation of progression-free survival at 6 months (PFS6) with overall survival at 12 months (OS12) in an analysis of 10 trials of second-line therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology. 30(15_suppl). 4525–4525. 3 indexed citations

19.

Liu, Ziyue, Sophia Chiu, Guru Sonpavde, et al.. (2012). Risk of venous thromboembolism in cancer patients treated with cisplatin: A systematic review and meta-analysis.. Journal of Clinical Oncology. 30(15_suppl). e21016–e21016. 2 indexed citations

20.

Sonpavde, Guru, В. Б. Матвеев, John M. Burke, et al.. (2011). Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Annals of Oncology. 23(7). 1803–1808. 118 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact